⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584588 | 1.00 | — | — | |
| SCHEMBL10304892 | 1.00 | — | — | |
| SCHEMBL13162267 | 1.00 | — | — | |
| SCHEMBL2146003 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL21521039 | 0.98 | GAA (0.33) | — | |
| Hydrochloric Acid SCHEMBL2146323 | 0.98 | GAA (0.33) | — | |
| Hydrochloric Acid SCHEMBL2146328 | 0.98 | GAA (0.33) | — | |
| SCHEMBL12824507 | 0.82 | — | — | |
| SCHEMBL18094005 | 0.81 | NOS3 (0.32) | — | |
| SCHEMBL16399313 | 0.81 | NOS3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017497-B2 | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3140297-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170217930-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-08-03 | — | — | US | disclosed |
| US-9714231-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3140297-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Bristol-Myers Squibb Company (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2925741-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| WO-2015171733-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2925741-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014078609-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |